Annual Report

There has been further good progress since the last Executive meeting. Following last year’s publication of the MGUS good practice paper (GPP), another GPP on smouldering myeloma has just been accepted for publication in the BJH and can now be viewed on the BSH Guidelines web page.  
Other guidelines are progressing well. GPPs on imaging in myeloma and high risk disease in transplant-eligible disease have been completed and submitted for review by the BSH Haem-onc Task Force and Guidelines Committee. The aim of the imaging GPP is to produce a document that reinforces the importance of functional imaging both at diagnosis and during the later management of myeloma patients.   
Other guidelines are “work in progress,” notably guidelines on the management of relapsed myeloma (Matt Jenner is lead author), which will need to be altered to take into account the recently published Cartitude-4 and Karmma-3 trial, and a GPP on MGRS. Other guidelines in their very early stages are on the management of myeloma bone disease and screening for amyloid in the outpatient setting. In addition, Jonathan Sive plans to initiate a GPP on myeloma serology testing.
I would like to thank all Executive members who are involved in the production of these guidelines and GPPs. Guideline production is the most active it has been in recent memory. 
Dr Simon Stern
Chair of UKMS Guidelines Group
March 2024

BSH/UKMS Guidelines

Click here to visit our BSH/UKMS Guidelines page.

About Us

Find out more about the UK Myeloma Society.

Find out more

BSH/UKMF Guidelines

Click here to visit our BSH/UKMF Guidelines page.

Position Statement

Find out more about our Position Statements by clicking here.